Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused

Plus: Hyperimmune Globulin Trial Launched

 
• By Scrip Team

NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.  

NIH
The ACTIV-3 Trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

More from Anti-infective

More from Therapy Areas